Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -61.32% is 25% above its 3-year average of -82.07%, near the high end of its 3-year range (-280.63%–-41.92%).
3.89% above its 12-month average of -63.80%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -73.10%.
NET PROFIT MARGIN
-61.32%
NET PROFIT MARGIN AVG TTM
-63.80%
NET PROFIT MARGIN AVG 3Y
-82.07%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+3.89%
CURRENT VS 3Y AVG
+25.29%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 690 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Beta Bionics, Inc.
Market Cap
$843.41M
Net Profit Margin
-61.32%
TTM Avg
-63.80%
3Y Avg
-82.07%
5Y Avg
N/A
Market Cap
$840.45M
Net Profit Margin
-39.20%
TTM Avg
-57.59%
3Y Avg
-24.68%
5Y Avg
-1.42%
Market Cap
$850.32M
Net Profit Margin
-5933.45%
TTM Avg
-505.88%
3Y Avg
-252.94%
5Y Avg
-252.94%
Market Cap
$835.90M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$865.85M
Net Profit Margin
-560.85%
TTM Avg
-63.69%
3Y Avg
-31.84%
5Y Avg
-21.23%
Market Cap
$817.67M
Net Profit Margin
-12.35%
TTM Avg
-13.43%
3Y Avg
-52.20%
5Y Avg
-503.49%
Market Cap
$826.20M
Net Profit Margin
-82.49%
TTM Avg
-271.33%
3Y Avg
-235.13%
5Y Avg
-173.69%
Market Cap
$805.59M
Net Profit Margin
20.69%
TTM Avg
35.62%
3Y Avg
36.75%
5Y Avg
38.26%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | $843.41M | -61.32% | -63.80% | -82.07% | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $840.45M | -39.20% | -57.59% | -24.68% | -1.42% |
| Alumis Inc. (ALMS)vs › | $850.32M | -5933.45% | -505.88% | -252.94% | -252.94% |
| Jade Biosciences, Inc. (JBIO)vs › | $835.90M | 0.00% | 0.00% | 0.00% | 0.00% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $865.85M | -560.85% | -63.69% | -31.84% | -21.23% |
| Ardelyx, Inc. (ARDX)vs › | $817.67M | -12.35% | -13.43% | -52.20% | -503.49% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $826.20M | -82.49% | -271.33% | -235.13% | -173.69% |
| Apnimed, Inc. (APMD)vs › | $804.43M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $805.59M | 20.69% | 35.62% | 36.75% | 38.26% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $893.04M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-69.8%
Net Profit Margin
-61.3%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -73.10% |
| 2026-03-31 | -79.26% |
| 2025-12-31 | -41.92% |
| 2025-09-30 | -52.14% |
| 2025-06-30 | -72.59% |
| 2025-03-31 | -162.46% |
| 2024-12-31 | -88.59% |
| 2024-09-30 | -58.28% |
| 2024-06-30 | -96.13% |
| 2024-03-31 | -96.26% |
| 2023-12-31 | -225.72% |
| 2023-09-30 | -280.63% |
